Drugs / L-ergothioneine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT03641404 Comparator | Aug 2019 → Dec 2023 | cognitive impairment with or without cerebellar ataxia | National University Hospital, Singapore | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | L-ergothioneine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03641404 ↗ |
| Route | Oral | “Subjects will consume 25mg ergothioneine (capsule), 3 times weekly (Monday, Wednesday, and Friday) for a total of 52 weeks.” NCT03641404 ↗ |